Amazon.Com, Inc. AMZN has received a warning from the U.S. Food and Drug Administration for selling and distributing certain unapproved eye drops, as these products are especially concerning from a public health perspective.
The seven eyedrops sold on the Amazon website, which the FDA does not approve, are - Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief, and Manzanilla Sophia Chamomile Herbal Eye Drops.
The regulatory agency said eye products generally risk consumer injury as they bypass some of the body's natural defenses.
Also Read: Amazon, Google And Microsoft To Invest $8.5B In Thailand's Digital Infrastructure
These seven products, some of which may temporarily relieve minor eye symptoms of excessive watery (clear) discharge, sensation of grittiness, redness, and burning, are not generally recognized as safe and effective (GRASE) by the FDA.
"Failure to adequately address this matter may result in legal action including, without limitation, seizure and/or injunction," the FDA letter added.
Further, the health regulator has also asked Amazon to ensure that it will no longer introduce, deliver, or cause the introduction or delivery into interstate commerce of ophthalmic unapproved new drug products.
The latest warning letter, dated Nov 13, follows the FDA's recently issued stern warning to the public, advising against the purchase and use of multiple specific over-the-counter eye drop products from prominent brands.
The brands associated with this warning include CVS Health Corporation CVS, Leader (owned by Cardinal Health, Inc CAH), Rugby (also a Cardinal Health brand), Rite Aid Corp.RADCQ, Target Corporation's TGT Up&Up and Velocity Pharma.
On Oct 25, the FDA recommended that the manufacturers recall all batches of the affected products.
Price Action: AMZN shares are trading higher by 0.73% to $146.87 premarket on the last checked Wednesday.
Photo Via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
